Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas
In conclusion, HER2 amplification is very rare in nonmetastatic treatment-naive cervical carcinomas, but if present, could represent a target for antibody therapy. ER and FAP were expressed in a subset of tumors, but expression did not correlate with clinical outcomes. These immunohistochemical markers do not demonstrate prognostic significance in treatment-naive cervical cancer, but they may have utility in targeted therapy or imaging.
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: Pathology of the Lower Tract: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Cervical Cancer | HER2 | Pathology | Squamous Cell Carcinoma